Navigation Links
BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
Date:11/21/2008

NOVATO, Calif., Nov. 21 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dr. Emil Kakkis, its Chief Medical Officer will retire from the company on February 27, 2009. Dr. Kakkis has decided to leave his position with the company to allow him to be able to devote more of his time to personal endeavors related to rare diseases. Dr. Kakkis will continue to be a consultant for the company for the foreseeable future.

"I am extremely grateful to have been part of this organization over the last ten years and to have been part of developing three novel treatments for rare genetic diseases. I would like to thank all of the patients, doctors and, particularly, the BioMarin employees that have helped me in those efforts. I am looking forward to the opportunity to devote additional time to developing an institute for rare diseases and legislation to support ultra-orphan drug development," said Dr. Kakkis.

"Emil has been an invaluable part of the leadership team here at BioMarin and we are sorry to see him leave. He has been instrumental in the development of all of BioMarin's products, dating back to the very early work that he did on Aldurazyme while he was on the faculty of UCLA and before he was an employee of BioMarin. We are very fortunate to have had his service and fortunate that he has agreed to continue helping the company on a consulting basis. Emil has done an excellent job building up the R&D organization, particularly in the past three years, and we have outstanding personnel in place to continue our innovation track and move forward with our current development plan," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin.

Dr. Kakkis joined BioMarin in September 1998. Prior to joining BioMarin, he was an assistant professor at th
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. BioMarin to Present at the BioCentury NewsMakers Conference
3. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
4. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
5. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
6. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
7. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
8. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
9. BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
10. BioMarin to Present at the Morgan Stanley Healthcare Conference
11. BioMarin Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 On Friday, December 19, ... the Omnibus and Continuing Resolution Appropriations Act of ... a condition eligible to receive funding through the ... the Department of Defense (DoD). The Hydrocephalus Association ... Capitol Hill, is celebrating this victory for the ...
(Date:12/24/2014)... 23, 2014 Nashville Fertility Center announced ... treasurer for the American Society for Reproductive Medicine (ASRM), ... research in reproductive medicine. In his new role ... the executive board and will have a voice in ... has actively supported ASRM since 1984 when he joined ...
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
Breaking Biology Technology:Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3
... Dissolve Powder Antacid Delivers Faster Relief, ... Increased Convenience and Great Taste, PITTSBURGH, April ... integrated marketing campaign,for the new TUMS(R) QuikPak(TM), the first and ... QuikPak campaign, part of,a larger new "Bring It On" brand ...
... - MIGENIX Inc.,(TSX: MGI, OTC: MGIFF), a clinical-stage ... Dorsman to its Board of Directors. Mr.,Dorsman is ... a,financial consulting firm in Vancouver, which advises companies ... overall business,strategies. Prior to founding his consulting firm ...
... Sirion Therapeutics, Inc., a,privately held ophthalmic-focused biopharmaceutical company, ... targeted for the,treatment of retinal diseases will be ... for Research in Vision and Ophthalmology (ARVO),April 27 ... http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO ), "We are very ...
Cached Biology Technology:New TUMS(R) QuikPak(TM) Campaign Offers Innovative Heartburn Relief with a Little Help from the Jetsons 2MIGENIX Appoints Pieter Dorsman to Board of Directors 2Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO 2Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO 3
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical ... building for its School of Medicine. Funding for this ... capital campaign that will be publicly launched next summer. ... located in the former 60 series R.J. Reynolds Tobacco ... Quarter. Construction will begin immediately with plans to be ...
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
(Date:12/5/2014)... 4, 2014 Increased emphasis on product ... new testing and inspection technologies. The convergence of ... a range of innovative test solutions. This trend ... Y, which is generally more inclined towards communication, ... development strategies of test equipment vendors will cater ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... Researchers at the University of Alabama at Birmingham (UAB) ... grow and remodel themselves to stay strong, a finding ... osteoporosis drugs, the researchers said The coupling factor ... or TGF beta-1. Previously, scientists had searched for but ...
... "Push your finger as hard as you can against the ... slowly - follow the ticking clock. Now faster. Now faster." ... experiment that casts doubt on old ideas about mechanisms to ... explain why manual dexterity is so vulnerable to aging and ...
... Ore. A 700-mile security wall under construction along ... the movement and "connectivity" of wildlife, biologists say, and ... of some species. However, technology and alterations to ... to move more freely between the two countries, the ...
Cached Biology News:UAB study reveals bone coupling factor key to skeletal health 21-finger exercise reveals unexpected limits to dexterity 21-finger exercise reveals unexpected limits to dexterity 3US-Mexico border wall could threaten wildlife species 2US-Mexico border wall could threaten wildlife species 3US-Mexico border wall could threaten wildlife species 4
Mouse monoclonal antibody raised against a partial recombinant PRG4. NCBI Entrez Gene ID = PRG4...
... selection system for recombinant identification. Recombinant selection ... need for costly color screening. This quick ... accuracy in recombinant selection. pLivSelect is also ... This cloning kit is customized as ...
The F40 pump maintenance kit is used to service one F40 pump of a BioLogic DuoFlow workstation. It includes 2 piston seals, 4 check valves, seal removal tool, and 2 O-rings....
... HDAC8 Regulation of gene expression ... as DNA methylation, ATP-dependent chromatin remodeling, ... which include the dynamic acetylation and ... residues present in the tail of ...
Biology Products: